Dholaria, Bhagirathbhai https://orcid.org/0000-0003-2371-3655
Bhaskar, Shakthi T.
Patel, Vivek G. https://orcid.org/0000-0003-4884-2947
Biltibo, Eden https://orcid.org/0000-0003-3222-4079
Jayani, Reena https://orcid.org/0000-0002-5291-5945
Sengsayadeth, Salyka
Jallouk, Andrew https://orcid.org/0000-0003-4335-7942
Jerkins, James https://orcid.org/0000-0002-2532-0604
Baer, Brittney
Nur, Ali
Baljevic, Muhamed https://orcid.org/0000-0002-0630-8458
Savani, Bipin N. https://orcid.org/0000-0002-3304-9965
Morgan, David
Kassim, Adetola A. https://orcid.org/0000-0002-0484-5903
Oluwole, Olalekan O. https://orcid.org/0000-0001-8525-9641
Funding for this research was provided by:
Gilead Sciences
Article History
Received: 20 January 2025
Revised: 18 February 2025
Accepted: 11 March 2025
First Online: 24 March 2025
Competing interests
: BD: Institutional research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir, Adicet, BMS, Molecular template, Atara. Consultancy/Advisor: MJH BioScience, Arivan Research, Janssen, ADC therapeutics, Gilead, GSK, Caribou, F. Hoffmann-La Roche AG, Autolus, Pierre Fabre.OO: Consultancy and advisory board for: Pfizer, Kite, Gilead, AbbVie, Janssen, TGR, ADC, Novartis, Caribou, Cargo, Epizyme, Nektar, Autolus, Allogene. Institution funding: Kite, Pfizer, Daichi Sankyo, Allogene. Honoraria: Pfizer, Gilead. EB: BeiGene (consulting). AJ: Kite-Gilead (consulting). MB: Consultancy: Pfizer, AbbVie Advisory Boards: BMS/Celgene, Janssen Biotech, Sanofi-Genzyme IRCs: Parexel International.
: This was an investigator-initiated study, sponsored by Vanderbilt University Medical Center, Nashville, TN, USA and funded by Gilead/Kite. The study was approved by institutional review board of Vanderbilt University (IRB #211221). Informed consent was obtained from the enrolled participants. The trial was conducted according to the Declaration of Helsinki and was registered on clinicatrials.gov ().